CytomX Therapeutics (CTMX)

• Market cap: $85.3M
• 1 day: -0.91%
• 5 days: -2.68%
• 1 month: 25.27%
• 3 months: -8.40%
• 6 months: -14.84%
• Year to date: -35.50%
• 1 year: -18.66%
• 5 years: -87.60%
• 10 years: -91.55%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Employees: 122

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1,330% more call options, than puts

Call options by funds: $143K | Put options by funds: $10K

0.24% more ownership

Funds ownership: 65.29% [Q2] → 65.53% (+0.24%) [Q3]

3% less capital invested

Capital invested by funds: $62.1M [Q2] → $60.3M (-$1.77M) [Q3]

7% less funds holding

Funds holding: 74 [Q2] → 69 (-5) [Q3]

22% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 23

33% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 15